for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Organogenesis Holdings Inc

ORGO.OQ

Latest Trade

5.11USD

Change

-0.01(-0.20%)

Volume

9,375

Today's Range

5.06

 - 

5.20

52 Week Range

2.49

 - 

5.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Organogenesis Holdings Files For Offering Of Up To 17.5 Million Shares Of Class A Common Stock

Nov 10 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::ORGANOGENESIS HOLDINGS INC FILES FOR OFFERING OF UP TO 17.5 MILLION SHARES OF CLASS A COMMON STOCK - SEC FILING.

Organogenesis Holdings Q3 Revenue Rises 57% To $100.8 Mln

Nov 9 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::. REPORTS THIRD QUARTER AND NINE MONTHS 2020 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.19.Q3 REVENUE ROSE 57 PERCENT TO $100.8 MILLION.SEES FY 2020 REVENUE $311 MILLION TO $314 MILLION.Q3 REVENUE ESTIMATE $72 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.ORGANOGENESIS HOLDINGS -EXPECTS TO REPORT POSITIVE GAAP NET INCOME AND POSITIVE ADJUSTED EBITDA FOR 3 MONTHS ENDED DEC 31.

Organogenesis Holdings Inc. Reports Preliminary Financial Results For Third Quarter 2020

Oct 14 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::. REPORTS PRELIMINARY FINANCIAL RESULTS FOR THIRD QUARTER 2020.SEES FY 2020 REVENUE $311 MILLION TO $314 MILLION.SEES NET REVENUE OF BETWEEN $99.0 MILLION AND $100.0 MILLION FOR THREE MONTHS ENDED SEPTEMBER 30, 2020.EXPECTS TO REPORT POSITIVE GAAP NET INCOME AND POSITIVE ADJUSTED EBITDA FOR THREE MONTHS ENDED DECEMBER 31, 2020.EXPECTS TO REPORT POSITIVE GAAP NET INCOME AND POSITIVE ADJUSTED EBITDA FOR FULL FISCAL YEAR 2020 PERIOD.EXPECTS TO REPORT POSITIVE GAAP NET INCOME AND POSITIVE ADJUSTED EBITDA FOR THREE MONTHS ENDED SEPTEMBER 30, 2020.

Organogenesis Holdings Inc. Announces Management Change

Organogenesis Holdings Inc <ORGO.O>::. ANNOUNCES MANAGEMENT CHANGE.SAYS CFO TIMOTHY M. CUNNINGHAM RESIGNED.ORGANOGENESIS HOLDINGS - HENRY HAGOPIAN HAS ASSUMED ROLE OF INTERIM CFO IN ADDITION TO HIS CURRENT RESPONSIBILITIES.INITIATED A SEARCH PROCESS TO IDENTIFY A PERMANENT CFO..

Organogenesis Holdings Reports Q2 Loss Per Share $0.05

Aug 10 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::REPORTS SECOND QUARTER AND FIRST HALF 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.05.Q2 REVENUE $69 MILLION VERSUS REFINITIV IBES ESTIMATE OF $58.8 MILLION.SEES FY 2020 REVENUE UP 5 TO 6 PERCENT.SEES FY 2020 REVENUE $273 MILLION TO $277 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.

Organogenesis Holdings Says Withdrawing Previously Announced Revenue Guidance For Fiscal Year Ending December 31, 2020

April 8 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::. REPORTS PRELIMINARY REVENUE RESULTS FOR FIRST QUARTER 2020.ORGANOGENESIS HOLDINGS - WITHDRAWING PREVIOUSLY ANNOUNCED REVENUE GUIDANCE FOR FISCAL YEAR ENDING DECEMBER 31, 2020.Q1 2020 PRELIMINARY NET REVENUE OF BETWEEN $61.0 MILLION AND $61.6 MILLION.ORGANOGENESIS HOLDINGS - ACTIVELY REVIEWING AND IMPLEMENTING COST SAVING MEASURES INCLUDING DISCONTINUING ALL NON-ESSENTIAL SERVICES AND PROGRAMS.COST SAVING MEASURES ALSO INCLUDE INSTITUTING CONTROLS ON TRAVEL, EVENTS, MARKETING AND CLINICAL STUDIES.Q1 REVENUE VIEW $60.6 MILLION -- REFINITIV IBES DATA.

Organogenesis Holdings Posts Quarterly Loss Per Share Of $0.04

March 9 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::. REPORTS FOURTH QUARTER AND FISCAL YEAR 2019 FINANCIAL RESULTS; INTRODUCES FISCAL YEAR 2020 REVENUE GUIDANCE.Q4 LOSS PER SHARE $0.04.Q4 REVENUE $74.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.4 MILLION.SEES FY 2020 REVENUE UP 5 TO 6 PERCENT.SEES FY 2020 REVENUE $273 MILLION TO $277 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $271.4 MILLION -- REFINITIV IBES DATA.

Organogenesis Holdings Reports Q4 Preliminary Revenue Results

Jan 13 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::. REPORTS PRELIMINARY REVENUE RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2019.SEES Q4 NET REVENUE OF BETWEEN $72.6 MILLION AND $74.6 MILLION.Q4 REVENUE VIEW $70.4 MILLION -- REFINITIV IBES DATA.

Organogenesis Holdings Announces Proposed Public Offering Of Class A Common Stock

Nov 19 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::ORGANOGENESIS HOLDINGS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF CLASS A COMMON STOCK.ORGANOGENESIS HOLDINGS INC SAYS OFFERING TO SELL 9.0 MILLION SHARES OF ITS CLASS A COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

Organogenesis Holdings Reports Third Quarter Results

Nov 12 (Reuters) - Organogenesis Holdings Inc <ORGO.O>::. REPORTS THIRD QUARTER AND NINE MONTHS OF 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.Q3 REVENUE $64.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $63 MILLION.SEES FY 2019 REVENUE UP 31 TO 34 PERCENT.Q3 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up